open access
Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report
Affiliations- Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University, Szczecin, Poland
open access
Abstract
Objectives: The aim of the present study was to compare the subjective quality of life in patients with overactive bladder (OAB) prior to intravesical botulinum toxin injection and three and six months thereafter. Material and methods: The study included 50 women diagnosed with OAB refractory to oral pharmacotherapy. The respondents completed four questionnaires, ICIQ-OAB, ICIQ-OABqol, ICIQ-LUTSqol and a dedicated clinicodemographic survey. Results: Intravesical injection of botulinum toxin A contributed to the attenuation of OAB-related ailments and resultant improvement of the quality of life. The ICIQ-OAB scores at three and six months post-injection were significantly lower than at the baseline (p < 0.001), implying that the treatment reduced the severity of OAB manifestations. OAB ailments had, without a doubt, a detrimental effect on the quality of life, as shown by high ICIQ-OABqol and ICIQ-LUTSqol scores before the treatment. Administration of botulinum toxin A was associated with a significant decrease in scores for all domains of the ICIQ-OABqol and ICIQ-LUTSqol scales (p < 0.001). Conclusions: Botulinum toxin is an effective treatment option in patients with OAB who failed to respond to anticholinergic therapy. Botulinum toxin injections contributed to a significant improvement in the quality of life during a six-month follow-up.
Abstract
Objectives: The aim of the present study was to compare the subjective quality of life in patients with overactive bladder (OAB) prior to intravesical botulinum toxin injection and three and six months thereafter. Material and methods: The study included 50 women diagnosed with OAB refractory to oral pharmacotherapy. The respondents completed four questionnaires, ICIQ-OAB, ICIQ-OABqol, ICIQ-LUTSqol and a dedicated clinicodemographic survey. Results: Intravesical injection of botulinum toxin A contributed to the attenuation of OAB-related ailments and resultant improvement of the quality of life. The ICIQ-OAB scores at three and six months post-injection were significantly lower than at the baseline (p < 0.001), implying that the treatment reduced the severity of OAB manifestations. OAB ailments had, without a doubt, a detrimental effect on the quality of life, as shown by high ICIQ-OABqol and ICIQ-LUTSqol scores before the treatment. Administration of botulinum toxin A was associated with a significant decrease in scores for all domains of the ICIQ-OABqol and ICIQ-LUTSqol scales (p < 0.001). Conclusions: Botulinum toxin is an effective treatment option in patients with OAB who failed to respond to anticholinergic therapy. Botulinum toxin injections contributed to a significant improvement in the quality of life during a six-month follow-up.
Keywords
botulinum toxin; overactive bladder; urinary incontinence; quality of life; onabotulinum toxin A
About this articleTitle
Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report
Journal
Issue
Article type
Research paper
Published online
2022-10-04
Page views
257
Article views/downloads
174
DOI
10.5603/GP.a2022.0105
Pubmed
Keywords
botulinum toxin
overactive bladder
urinary incontinence
quality of life
onabotulinum toxin A
Authors
Agnieszka Licow
Sylwester Ciecwiez
Agnieszka Brodowska
References (29)- Haylen BT, de Ridder D, Freeman RM, et al. International Urogynecological Association, International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29(1): 4–20.
- Khizer Z, Sadia A, Sharma R, et al. Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review. Pharmaceuticals (Basel). 2021; 14(5).
- Hutchinson A, Nesbitt A, Joshi A, et al. Overactive bladder syndrome: Management and treatment options. Aust J Gen Pract. 2020; 49(9): 593–598.
- Ptashnyk T, Hatzinger M, Zeller FL, et al. Overactive bladder syndrome - focus onto detrusor overactivity. Scand J Urol. 2021; 55(1): 56–60.
- Takahashi S, Takei M, Asakura H, et al. Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition). Int J Urol. 2021; 28(5): 474–492.
- Carruthers A, Carruthers J. Dover Jeffrey S, Toksyna botulinowa. Dermatologia kosmetyczna. 1. wyd. Edra Urban & Partner, Wroclaw 2019.
- Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002; 11(6): 563–574.
- Hebbar S, Pandey H, Chawla A. Understanding King's Health Questionnaire (KHQ) in assessment of female urinary incontinence. Int J Res Med Sci. 2015; 3(3): 531–538.
- Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, et al. OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J. 2021; 32(1): 65–74.
- Tamburro FR, Castellan P, Neri F, et al. Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. Urologia. 2018; 85(4): 163–168.
- Juszczak K, Adamczyk P, Maciukiewicz P, et al. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder. Pharmacol Rep. 2018; 70(6): 1133–1138.
- Rechberger T, Miotła P, Skorupski P, et al. Jakość życia pacjentek z pęcherzem nadreaktywnym po zastosowaniu toksyny botulinowej - doniesienie wstępne. Ginekol Pol. 2010; 81(1): 24–30.
- Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013; 64(2): 249–256.
- Nitti VW, Dmochowski R, Herschorn S, et al. EMBARK Study Group, EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013; 189(6): 2186–2193.
- Fowler CJ, Auerbach S, Ginsberg D, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012; 62(1): 148–157.
- Sahai A, Dowson C, Khan MS, et al. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int. 2009; 103(11): 1509–1515.
- Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017; 24(3): 8838–8846.
- Zhou X, Yan HL, Cui YS, et al. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl). 2015; 128(7): 963–968.
- Honda M, Yokoyama O, Takahashi R, et al. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension. Int J Urol. 2021; 28(9): 906–912.
- Martins-Silva C, Cruz F. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. Eur Urol Focus. 2016; 2(3): 329–331.
- Yuan H, Cui Y, Wu J, et al. Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J. 2017; 21(1): 53–61.
- Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013; 32(3): 242–249.
- Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013; 81(9): 841–848.
- Austin PF, Franco I, Dobremez E, et al. OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children. Neurourol Urodyn. 2021; 40(1): 493–501.
- Khan MK, VanderBrink BA, DeFoor WR, et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol. 2016; 12(2): 104.e1–104.e6.
- El-Dakhakhny AS, El-Karamany TM, El-Atrebi M, et al. Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study. Arab J Urol. 2019; 17(2): 143–149.
- Ringoir A, Dhondt B, De Bleser E, et al. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study. J Pediatr Urol. 2020; 16(2): 181.e1–181.e8.
- Christiansen FE, Pedersen TB, Juel J, et al. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population. Scand J Urol. 2017; 51(5): 392–396.
- Ginsberg DA, Drake MJ, Kaufmann A, et al. 191622-096 Investigators. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. J Urol. 2017; 198(4): 897–904.
